FOR IMMEDIATE RELEASE
March 5, 2009
Contact: Maria Stecklein
816.223.2662
maria@orbisbio.com
Orbis Biosciences a contender for “World’s Best Technology” Title
Controlled Release Technology invited to present the 2009 WBTshowcase
March 5, 2009 | Arlington, TX – Orbis Biosciences will be among the top technology innovators from around the world presenting at the March 24-25 WBTshowcase in Arlington, Texas.
Orbis Biosciences microparticle technology, which provides unprecedented control of release rate of any material, was rigorously screened and mentored by WBTshowcase commercialization experts to present to an audience including over 100 venture investors and Fortune 500 licensees.
“Orbis Biosciences technology has so many applications – from creating longer-lasting drugs to extending a pesticide’s efficacy to taste masking a bitter nutrient in a sports drink – that the opportunity to connect with companies searching for controlled release solutions is very valuable,” said Bo Fishback, Orbis Biosciences CEO.
Each year, just one of the WBTshowcase’s carefully selected presenters receives the "Best of Show" award.
Mr. Huleatt highlighted that the companies groomed to present at the WBTshowcase leave with new knowledge and contact to take their technologies to market and beyond.
“The revolutionary nature of the technologies presenting at the WBTshowcase makes it a must-attend event for investors and licensing scouts,” said Paul Huleatt, WBTshowcase CEO.
The WBTshowcase is the nation's premier event showcasing the largest collection of undiscovered technologies emanating from the world’s leading universities, labs and research institutions.
The 2008 World’s Best Technologies Showcase brought together over 75 world-class deals and attracted over 450 attendees including over 100 bonafide investors and Fortune 1000 licensees.
According to Mr. Huleatt, approximately 1/3 of past WBTshowcase presenters have gone on to secure venture capital or a licensing/strategic partnering agreement with a Fortune 500 company. To date, past presenters have raised over $400 million in first (or next) round venture capital.
ABOUT Orbis Biosciences
Orbis Biosciences offers the ability to control the size, shell thickness, porosity, and uniformity of nearly any material with a level of scalability previously impossible. From drug formulations, to agricultural compounds to novel food processing techniques, Orbis Biosciences provides solutions for controlled release.
http://www.orbisbio.com/